- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging drugs for the treatment of hemophilia A and B
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 21, Issue 3, Pages 301-313
Publisher
Informa UK Limited
Online
2016-08-11
DOI
10.1080/14728214.2016.1220536
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
- (2016) E. Santagostino et al. BLOOD
- Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study
- (2016) M. Morfini et al. HAEMOPHILIA
- Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials
- (2016) C. Negrier et al. HAEMOPHILIA
- A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
- (2016) Flora Peyvandi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
- (2016) Midori Shima et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4)
- (2016) Guy Young et al. THROMBOSIS RESEARCH
- Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
- (2015) B. A. Konkle et al. BLOOD
- A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
- (2015) N. Uchida et al. BLOOD
- Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003
- (2015) Jan Blatny et al. BLOOD COAGULATION & FIBRINOLYSIS
- How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access
- (2015) A. Nijdam et al. HAEMOPHILIA
- Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety
- (2015) T. Lissitchkov et al. HAEMOPHILIA
- Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics
- (2015) A. Klukowska et al. HAEMOPHILIA
- Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII
- (2015) A. Shah et al. HAEMOPHILIA
- BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial
- (2015) R. Ljung et al. HAEMOPHILIA
- Half-life extended factor VIII for the treatment of hemophilia A
- (2015) A. Tiede JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
- (2015) K. Kavakli et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A
- (2015) G. Young et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
- (2015) P. Chowdary et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
- (2015) Alfica Sehgal et al. NATURE MEDICINE
- Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line
- (2015) Stefan Winge et al. PROTEIN EXPRESSION AND PURIFICATION
- Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A
- (2014) A. Muto et al. BLOOD
- Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
- (2014) P. W. Collins et al. BLOOD
- Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study
- (2014) Jerry S. Powell et al. BRITISH JOURNAL OF HAEMATOLOGY
- Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
- (2014) Lei Diao et al. CLINICAL PHARMACOKINETICS
- Turoctocog alfa (NovoEight®) - from design to clinical proof of concept
- (2014) Mirella Ezban et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration
- (2014) Henrik Agersø et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey
- (2014) M. Franchini et al. HAEMOPHILIA
- Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™clinical trials
- (2014) E. Santagostino et al. HAEMOPHILIA
- Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
- (2014) T. E. Coyle et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII
- (2014) Sabine Zollner et al. THROMBOSIS RESEARCH
- A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
- (2013) H. R. Stennicke et al. BLOOD
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
- (2013) J. Mahlangu et al. BLOOD
- Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
- (2013) S. C. Gouw et al. BLOOD
- Purchasing factor concentrates in the 21st century through competitive tendering
- (2013) C. R. M. Hay HAEMOPHILIA
- Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics
- (2013) R. Kulkarni et al. HAEMOPHILIA
- Establishing a harmonized haemophilia registry for countries with developing health care systems
- (2013) A. Alzoebie et al. HAEMOPHILIA
- Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy
- (2013) S. R. Lentz et al. HAEMOPHILIA
- Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression
- (2013) M. Xi et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A
- (2013) A. Tiede et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
- (2013) Jerry S. Powell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factor VIII Products and Inhibitor Development in Severe Hemophilia A
- (2013) Samantha C. Gouw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
- (2013) Zenjiro Sampei et al. PLoS One
- Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII
- (2013) Sabine B. Zollner et al. THROMBOSIS RESEARCH
- Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz–type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor
- (2013) Lene Hansen et al. THROMBOSIS RESEARCH
- How we choose factor VIII to treat hemophilia
- (2012) P. M. Mannucci et al. BLOOD
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
- (2012) J. S. Powell et al. BLOOD
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
- (2012) E. Santagostino et al. BLOOD
- Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model
- (2012) I. Hilden et al. BLOOD
- The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics
- (2012) Elisabeth Casademunt et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Management of bleeding disorders in the elderly
- (2012) R. KRUSE-JARRES et al. HAEMOPHILIA
- Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis
- (2012) U. Martinowitz et al. HAEMOPHILIA
- Health technology assessment and haemophilia
- (2012) A. FARRUGIA et al. HAEMOPHILIA
- Hemostatic properties of a TFPI antibody
- (2012) Lars C. Petersen THROMBOSIS RESEARCH
- Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII
- (2012) Helena Sandberg et al. THROMBOSIS RESEARCH
- Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII
- (2012) Christoph Kannicht et al. THROMBOSIS RESEARCH
- Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening
- (2012) J. Michael Soucie et al. TRANSFUSION
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
- (2011) A. D. Shapiro et al. BLOOD
- Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
- (2011) C. Negrier et al. BLOOD
- Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor
- (2011) E. K. Waters et al. BLOOD
- Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review
- (2011) Massimo Franchini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A
- (2011) U. MARTINOWITZ et al. HAEMOPHILIA
- Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies
- (2011) L. M. ALEDORT et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
- (2011) A. GRINGERI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation
- (2011) L. A. PARUNOV et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
- (2010) B. Mei et al. BLOOD
- Patient and parent preferences for haemophilia A treatments
- (2010) A. F. MOHAMED et al. HAEMOPHILIA
- Purification and characterization of a new recombinant factor VIII (N8)
- (2009) L. THIM et al. HAEMOPHILIA
- A study of reported factor VIII use around the world
- (2009) J. S. STONEBRAKER et al. HAEMOPHILIA
- Half-life extension through albumin fusion technologies
- (2009) Stefan Schulte THROMBOSIS RESEARCH
- Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities
- (2008) M.-C. POON et al. HAEMOPHILIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now